-
Wedge Resection versus Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors ≤8 mm Curr. Oncol. (IF 2.6) Pub Date : 2024-03-15 Arian Mansur, Zain Saleem, Jorind Beqari, Camille Mathey-Andrews, Alexandra L. Potter, James Cranor, Alexandra T. Nees, Deepti Srinivasan, Margaret E. Yang, Chi-Fu Jeffrey Yang, Hugh G. Auchincloss
The objective of this study was to evaluate the overall survival of patients with ≤8 mm non-small cell lung cancer (NSCLC) who undergo wedge resection versus stereotactic body radiation therapy (SBRT). Kaplan–Meier analysis, multivariable Cox proportional hazards modeling, and propensity score-matched analysis were performed to evaluate the overall survival of patients with ≤8 mm NSCLC in the National
-
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma Curr. Oncol. (IF 2.6) Pub Date : 2024-03-15 Tasuku Nakabori, Sena Higashi, Yutaro Abe, Kaori Mukai, Toshiki Ikawa, Koji Konishi, Noboru Maeda, Katsuyuki Nakanishi, Shinichiro Hasegawa, Hiroshi Wada, Kazuyoshi Ohkawa
Various locoregional treatments for localized hepatocellular carcinoma (HCC) have been developed. This retrospective study investigated the safety and feasibility of combining on-demand selective locoregional treatment for residual lesions after tumor shrinkage (complete response [CR] oriented) or for solitary or few drug-resistant lesions (progressive disease (PD) salvage) with first-line atezolizumab
-
The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE) Curr. Oncol. (IF 2.6) Pub Date : 2024-03-13 Natale Quartuccio, Salvatore Ialuna, Daniele Scalisi, Fabio D’Amato, Maria Rosa Barcellona, Maria Grazia Bavetta, Giorgio Fusco, Enrico Bronte, Emma Musso, Fabrizio Bronte, Viviana Picciotto, Antonio Carroccio, Francesco Verderame, Giuseppe Malizia, Angelina Cistaro, Fabio La Gattuta, Antonino Maria Moreci
The aim of this study was to present our preliminary experience with transarterial radioembolization (TARE) using Yttrium-90 (90Y), compare the cancer-specific survival (CSS) of patients with hepatocellular carcinoma (HCC) and colorectal cancer (CRC) liver metastases undergoing TARE, and investigate the influence of additional treatments on CSS. Our database was interrogated to retrieve patients who
-
Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre Curr. Oncol. (IF 2.6) Pub Date : 2024-03-14 Katelyn E Fleming, Ava Hupel, Hamid Mithoowani, Tea Lulic-Kuryllo, Mario Valdes
Timely reporting of molecular biomarkers is critical in guiding optimal treatment decisions in patients with advanced non-small cell lung carcinoma (NSCLC). Any delays along the tissue or treatment pathway may be associated with suboptimal treatment/outcomes and a reduced quality of life. For many centres, biomarkers are tested off-site. Methods: A retrospective chart review of 123 patients with advanced
-
Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations Curr. Oncol. (IF 2.6) Pub Date : 2024-03-09 Miklos Acs, Pompiliu Piso, Gabriel Glockzin
Peritoneal metastasis is a common finding in patients with advanced gastric cancer. Beyond systemic chemotherapy, additive local treatments such as cytoreductive surgery and intraperitoneal chemotherapy are considered an inherent part of different multimodal treatment concepts for selected patients with peritoneal metastatic gastric cancer. This review article discusses the role of cytoreductive surgery
-
A Retrospective Age Analysis of the Ambulatory Oncology Patient Satisfaction Survey: Differences in Satisfaction across Dimensions of Person-Centred Care and Unmet Needs among Older Adults Receiving Cancer Treatment Curr. Oncol. (IF 2.6) Pub Date : 2024-03-13 Fay J. Strohschein, Siwei Qi, Sandra Davidson, Claire Link, Linda Watson
Over half of all new cancer cases in Alberta are diagnosed among people aged 65+ years, a group that encompasses vast variation. Patient-reported experience measures are routinely collected within Cancer Care Alberta; however, the specific consideration of the needs and concerns of older Albertans with cancer is lacking. In 2021, 2204 adults who had received treatment at a cancer centre in Alberta
-
Overview of the Engagement Process to Develop the Future of Cancer Impact (FOCI) Report in Alberta: The Power of Collective Action Curr. Oncol. (IF 2.6) Pub Date : 2024-03-12 Anna Pujadas Botey, Tara R. Bond, Eliya Farah, Chantelle Carbonell, Stacey Dyck, Angela Estey, Douglas A. Stewart, Darren R. Brenner, Paula J. Robson
This commentary provides a detailed overview of the extensive stakeholder engagement efforts critical to the development of the Future of Cancer Impact (FOCI) in Alberta report. The overarching aim of the FOCI report was to support informed and strategic discussions and actions that will help key stakeholders in the province prepare for a future with increasing cancer incidence and survival. Employing
-
Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report Curr. Oncol. (IF 2.6) Pub Date : 2024-03-12 Hiroo Imai, Ken Saijo, Noriko Takenaga, Keigo Komine, Kota Ouchi, Yuki Kasahara, Shiori Ishikawa, Keiju Sasaki, Yuya Yoshida, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Chylous ascites is a rare form of ascites with high triglyceride content arising from the thoracoabdominal lymph nodes in the peritoneal cavity due to various benign or malignant etiologies, including pancreatic cancer. During cancer chemotherapy, the accumulation of ascites can lead to the deterioration of the patient’s general condition, making chemotherapy administration difficult, and resulting
-
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action Curr. Oncol. (IF 2.6) Pub Date : 2024-03-11 Sandeep Sehdev, Joanna Gotfrit, Martine Elias, Barry D. Stein
Canada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to identify studies associated with the clinical, economic, and quality of life impacts of delayed
-
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development Curr. Oncol. (IF 2.6) Pub Date : 2024-03-08 Dennis Dong Hwan Kim, Gizelle Popradi, Kylie Lepic, Kristjan Paulson, David Allan, Ram Vasudevan Nampoothiri, Sylvie Lachance, Uday Deotare, Jennifer White, Mohamed Elemary, Kareem Jamani, Christina Fraga, Christopher Lemieux, Igor Novitzky-Basso, Arjun Law, Rajat Kumar, Irwin Walker, Kirk R. Schultz
This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories
-
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice Curr. Oncol. (IF 2.6) Pub Date : 2024-03-07 Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed
-
The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy Curr. Oncol. (IF 2.6) Pub Date : 2024-03-08 Laura Hopkins, Mark Carey, Linda Brown, Sabryna McCrea, Mark Milne, Dawne Tokaryk, Dawn Stacey
New treatments for ovarian cancer are available that require trade-offs between progression-free survival and quality of life. The aim of this study was to develop a decision aid for patients with homologous recombinant proficient (HRP) tumors, as the benefit–harm ratio of niraparib needs consideration. This decision aid was created with a systematic and iterative development process based on the Ottawa
-
Outpatient Embedded Palliative Care for Patients with Advanced Thoracic Malignancy: A Retrospective Cohort Study Curr. Oncol. (IF 2.6) Pub Date : 2024-03-07 Mary C. Boulanger, Margaret D. Krasne, Ethan K. Gough, Samantha Myers, Ilene S. Browner, Josephine L. Feliciano
Although cancer care is often contextualized in terms of survival, there are other important cancer care outcomes, such as quality of life and cost of care. The ASCO Value Framework assesses the value of cancer therapies not only in terms of survival but also with consideration of quality of life and financial cost. Early palliative care for patients with advanced cancer is associated with improved
-
A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia Curr. Oncol. (IF 2.6) Pub Date : 2024-03-04 Lilit Harutyunyan, Evelina Manvelyan, Nune Karapetyan, Samvel Bardakhchyan, Aram Jilavyan, Gevorg Tamamyan, Armen Avagyan, Liana Safaryan, Davit Zohrabyan, Narine Movsisyan, Anna Avinyan, Arevik Galoyan, Mariam Sargsyan, Martin Harutyunyan, Hasmik Nersoyan, Arevik Stepanyan, Armenuhi Galstyan, Samvel Danielyan, Armen Muradyan, Gagik Jilavyan
Background: Annually, approximately 200 new ovarian cancer cases are diagnosed in Armenia, which is considered an upper-middle-income country. This study aimed to summarize the survival outcomes of patients with relapsed ovarian cancer in Armenia based on the type of recurrence, risk factors, and choice of systemic treatment. Methods: This retrospective case-control study included 228 patients with
-
Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital Curr. Oncol. (IF 2.6) Pub Date : 2024-03-05 Aline Rozman de Moraes, Elif Erdogan, Ahsan Azhar, Suresh K. Reddy, Zhanni Lu, Joshua A. Geller, David Mill Graves, Michal J. Kubiak, Janet L. Williams, Jimin Wu, Eduardo Bruera, Sriram Yennurajalingam
Background: Our aim was to examine the frequency and prescription pattern of breakthrough (BTO) and scheduled (SCH) opioids and their ratio (BTO/SCH ratio) of use, prior to and after referral to an inpatient supportive care consult (SCC) for cancer pain management (CPM). Methods and Materials: Patients admitted at the MD Anderson Cancer Center and referred to a SCC were retrospectively reviewed. Cancer
-
Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada Curr. Oncol. (IF 2.6) Pub Date : 2024-03-06 Stephanie Snow, Christine Brezden-Masley, Michael D. Carter, Neesha Dhani, Cassandra Macaulay, Ravi Ramjeesingh, Michael J. Raphael, Monika Slovinec D’Angelo, Filomena Servidio-Italiano
Genomic medicine is a powerful tool to improve diagnosis and outcomes for cancer patients by facilitating the delivery of the right drug at the right dose at the right time for the right patient. In 2023, a Canadian conference brought together leaders with expertise in different tumor types. The objective was to identify challenges and opportunities for change in terms of equitable and timely access
-
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care Curr. Oncol. (IF 2.6) Pub Date : 2024-03-06 Ana-Alicia Beltran-Bless, Mark Clemons, Lisa Vandermeer, Khaled El Emam, Terry L. Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
Patients, families, healthcare providers and funders face multiple comparable treatment options without knowing which provides the best quality of care. As a step towards improving this, the REthinking Clinical Trials (REaCT) pragmatic trials program started in 2014 to break down many of the traditional barriers to performing clinical trials. However, until other innovative methodologies become widely
-
Ovarian Cancer in the Older Manitoban Population—Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study Curr. Oncol. (IF 2.6) Pub Date : 2024-03-05 Lesley F. Roberts, Pascal Lambert, Mark W. Nachtigal, Alon D. Altman, Erin Dean
Background: In Canada, individuals with gynecologic reproductive organs (ovaries, fallopian tubes, uterus) over the age of 70 comprise a large proportion of epithelial ovarian cancer patients. These patients often have co-morbidities, polypharmacy, or decreased functional status that may impact treatment initiation and tolerance. Despite this, there is limited evidence to guide treatment for older
-
ITGAV Promotes the Progression of Head and Neck Squamous Cell Carcinoma Curr. Oncol. (IF 2.6) Pub Date : 2024-03-01 Lingyi Xu, Jeremy G Barrett, Jiayi Peng, Suk Li, Diana Messadi, Shen Hu
Head and neck squamous cell carcinoma (HNSCC) refers to the malignancy of squamous cells in the head and neck region. Ranked as the seventh most common cancer worldwide, HNSCC has a very low survival rate, highlighting the importance of finding therapeutic targets for the disease. Integrins are cell surface receptors that play a crucial role in mediating cellular interactions with the extracellular
-
Timing of Surgery and Social Determinants of Health Related to Pathologic Complete Response after Total Neoadjuvant Therapy for Rectal Adenocarcinoma: Retrospective Study of National Cancer Database Curr. Oncol. (IF 2.6) Pub Date : 2024-02-29 Megan Mai, Jodi Goldman, Duke Appiah, Ramzi Abdulrahman, John Kidwell, Zheng Shi
Total neoadjuvant therapy (TNT) for rectal adenocarcinoma (RAC) involves multi-agent chemotherapy and radiation before definitive surgery. Previous studies of the rest period (time between radiation and surgery) and pathologic complete response (pCR) have produced mixed results. The objective of this study was to evaluate the relationship between the rest period and pCR. This study utilized the National
-
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland Curr. Oncol. (IF 2.6) Pub Date : 2024-03-01 Lynda M. McSorley, Mehala Tharmabala, Fathiya Al Rahbi, Fergus Keane, Denis Evoy, James G. Geraghty, Jane Rothwell, Damian P. McCartan, Megan Greally, Miriam O’Connor, Deirdre O’Mahony, Maccon Keane, Michael John Kennedy, Seamus O’Reilly, Steve J. Millen, John P. Crown, Catherine M. Kelly, Ruth S. Prichard, Cecily M. Quinn, Janice M. Walshe
Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational study was undertaken between 2011 and 2019 on a cross-section of hormone receptor-positive (HR+), HER2-negative, lymph node-negative, early-stage breast cancer
-
Adapting an Adolescent and Young Adult Program Housed in a Quaternary Cancer Centre to a Regional Cancer Centre: Creating Equitable Access to Developmentally Tailored Support Curr. Oncol. (IF 2.6) Pub Date : 2024-02-27 Marlie Smith, Simone Kurup, Kaviya Devaraja, Shaayini Shanawaz, Lorrie Reynolds, Jill Ross, Andrea Bezjak, Abha A. Gupta, Alisha Kassam
Adolescents and young adults (AYAs) with cancer, representing those between 15 and 39 years of age, face distinctive challenges balancing their life stage with the physical, emotional, and social impacts of a cancer diagnosis. These challenges include fertility concerns, disruptions to educational and occupational pursuits, issues related to body image and sexual health, and the need for age-appropriate
-
High Symptom Burden in Patients Receiving Radiotherapy and Factors Associated with Being Offered an Intervention Curr. Oncol. (IF 2.6) Pub Date : 2024-02-27 Allison Rau, Demetra Yannitsos, Petra Grendarova, Siwei Qi, Linda Watson, Lisa Barbera
Patient report outcomes are commonly collected during oncology visits to elicit symptom burden and guide management. We aimed to determine the frequency of intervention for patients undergoing radiotherapy with high symptom complexity scores and identify which factors are associated with being offered an intervention. A retrospective chart audit was completed of adult patients with cancer who had at
-
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study Curr. Oncol. (IF 2.6) Pub Date : 2024-02-27 Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F. K. Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most benefit from molecular assays and where this test may be of poor value. In this multicenter prospective
-
Modeling 5-FU-Induced Chemotherapy Selection of a Drug-Resistant Cancer Stem Cell Subpopulation Curr. Oncol. (IF 2.6) Pub Date : 2024-02-25 Amra Ramović Hamzagić, Danijela Cvetković, Marina Gazdić Janković, Nevena Milivojević Dimitrijević, Dalibor Nikolić, Marko Živanović, Nikolina Kastratović, Ivica Petrović, Sandra Nikolić, Milena Jovanović, Dragana Šeklić, Nenad Filipović, Biljana Ljujić
(1) Background: Cancer stem cells (CSCs) are a subpopulation of cells in a tumor that can self-regenerate and produce different types of cells with the ability to initiate tumor growth and dissemination. Chemotherapy resistance, caused by numerous mechanisms by which tumor tissue manages to overcome the effects of drugs, remains the main problem in cancer treatment. The identification of markers on
-
Colorectal Cancer Patients’ Reported Frequency, Content, and Satisfaction with Advance Care Planning Discussions Curr. Oncol. (IF 2.6) Pub Date : 2024-02-26 Said Hussein, Chloe Ahryung Lim, Thulasie Manokaran, Shireen Kassam, Madalene Earp, Patricia A. Tang, Safiya Karim, Patricia Biondo, Sharon M. Watanabe, Aynharan Sinnarajah, Amy Tan, Jessica Simon
(1) Background: This observational cohort study describes the frequency, content, and satisfaction of advance care planning (ACP) conversations with healthcare providers (HCPs), as reported by patients with advanced colorectal cancer. (2) Methods: The patients were recruited from two tertiary cancer centers in Alberta, Canada. Using the My Conversations survey with previously validated questions, the
-
Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience Curr. Oncol. (IF 2.6) Pub Date : 2024-02-26 Vered Stavi, Niranjan Khaire, Jeffrey H. Lipton, Rajat Kumar
Severe aplastic anemia (SAA) is a life-threatening type of aplastic anemia for which allogeneic stem cell transplantation or immunosuppressive therapy are the principal treatment modalities. Only about 25–30% of patients have a matched sibling donor, and finding an unrelated donor in ethnic minorities is a challenge. The use of related haploidentical donor transplants in severe aplastic anemia is uncommon
-
Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine Curr. Oncol. (IF 2.6) Pub Date : 2024-02-23 Dilip R. Gunturu, Mohammed Hassan, Deepa Bedi, Pran Datta, Upender Manne, Temesgen Samuel
Precision cancer medicine primarily aims to identify individual patient genomic variations and exploit vulnerabilities in cancer cells to select suitable patients for specific drugs. These genomic features are commonly determined by gene sequencing prior to therapy, to identify individuals who would be most responsive. This precision approach in cancer therapeutics remains a powerful tool that benefits
-
Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-02-22 Nikolaos Kalampokis, Christos Zabaftis, Theodoros Spinos, Markos Karavitakis, Ioannis Leotsakos, Ioannis Katafigiotis, Henk van der Poel, Nikolaos Grivas, Dionysios Mitropoulos
(1) Background: Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance as genetic biomarkers. (2) Methods: A narrative review of all the available literature was performed
-
The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-02-24 Iveta Kolářová, Bohuslav Melichar, Igor Sirák, Jaroslav Vaňásek, Jiří Petera, Kateřina Horáčková, Denisa Pohanková, Filip Ďatelinka, Zuzana Šinkorová, Milan Vošmik
The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers
-
Sex-Based Analysis of Quality Indicators of End-of-Life Care in Gastrointestinal Malignancies Curr. Oncol. (IF 2.6) Pub Date : 2024-02-22 Caitlin S. Lees, Hsien Seow, Kelvin K. W. Chan, Anastasia Gayowsky, Shaila J. Merchant, Aynharan Sinnarajah
Indices of aggressive or supportive end-of-life (EOL) care are used to evaluate health services quality. Disparities according to sex were previously described, with studies showing that male sex is associated with aggressive EOL care. This is a secondary analysis of 69,983 patients who died of a GI malignancy in Ontario between 2006 and 2018. Quality indices from the last 14–30 days of life and aggregate
-
Spatially Resolved Microglia/Macrophages in Recurrent Glioblastomas Overexpress Fatty Acid Metabolism and Phagocytic Genes Curr. Oncol. (IF 2.6) Pub Date : 2024-02-23 Akshitkumar M. Mistry, Jonah Daneshmand, SeonYeong Jamie Seo, Norman L. Lehman, Donald M. Miller, Dylan A. Goodin, Hermann B. Frieboes, Joseph Chen, Adrianna Masters, Brian J. Williams, Kavitha Yaddanapudi
Background: Glioblastoma (GBM) tumors are rich in tumor-associated microglia/macrophages. Changes associated with treatment in this specific cell population are poorly understood. Therefore, we studied changes in gene expression of tumor-associated microglia/macrophages (Iba1+) cells in de novo versus recurrent GBMs. Methods: NanoString GeoMx® Digital Spatial Transcriptomic Profiling of microglia/macrophages
-
Extended Right Hepatectomy following Clearance of the Left Liver Lobe and Portal Vein Embolization for Curatively Intended Treatment of Extensive Bilobar Colorectal Liver Metastases: A Single-Center Case Series Curr. Oncol. (IF 2.6) Pub Date : 2024-02-21 Sebastian Knitter, Linda Sauer, Karl-H. Hillebrandt, Simon Moosburner, Uli Fehrenbach, Timo A. Auer, Nathanael Raschzok, Georg Lurje, Felix Krenzien, Johann Pratschke, Wenzel Schöning
Background: Two-staged hepatectomy (TSH) including portal vein embolization (PVE) may offer surgical treatment for extensive bilobar colorectal liver metastases (CRLM). This study aimed to investigate the feasibility and outcomes of extended right hepatectomy (ERH) within TSH including PVE for patients with extended CRLM. Methods: We retrospectively collected data of patients who underwent TSH for
-
Lung Cancer Prevalence in Virginia: A Spatial Zipcode-Level Analysis via INLA Curr. Oncol. (IF 2.6) Pub Date : 2024-02-20 Indranil Sahoo, Jinlei Zhao, Xiaoyan Deng, Myles Gordon Cockburn, Kathy Tossas, Robert Winn, Dipankar Bandyopadhyay
Background: Examining lung cancer (LC) cases in Virginia (VA) is essential due to its significant public health implications. By studying demographic, environmental, and socioeconomic variables, this paper aims to provide insights into the underlying drivers of LC prevalence in the state adjusted for spatial associations at the zipcode level. Methods: We model the available VA zipcode-level LC counts
-
Vitiligo-Like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center Curr. Oncol. (IF 2.6) Pub Date : 2024-02-19 João Queirós Coelho, Raquel Romão, Maria João Sousa, Sérgio Xavier Azevedo, Paula Fidalgo, António Araújo
The reference to vitiligo-like lesions (VLLs) induced by immune checkpoint inhibitors (ICIs) as a valuable predictive marker of treatment success of immunotherapy with ICIs in melanoma has been mentioned in the literature. Its role in non-small cell lung cancer (NSCLC)-treated patients remains a poorly recognized phenomenon with uncertain significance regarding its predictive value. A retrospective
-
Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region Curr. Oncol. (IF 2.6) Pub Date : 2024-02-18 Letícia Pacheco Porangaba, Flávio de Melo Garcia, Ana Paula Alvarenga Antonio Rabelo, Amanda Puche Andrade, Fabio de Abreu Alves, Antonio Cássio Assis Pellizzon, Graziella Chagas Jaguar
This study aims to compare whether the use of a salivary substitute including an enzymatic system clinically reduces the intensity of xerostomia, as well as exploring the impact that this has on the quality of life, in patients who had received radiotherapy in the head and neck (HNC) region. Forty patients who had completed radiotherapy treatment within 6 months to 1 year previously were allocated
-
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology Curr. Oncol. (IF 2.6) Pub Date : 2024-02-15 Anupam Batra, Daniel Glick, Mario Valdes
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy
-
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-02-16 Sarah Lidagoster, Reuben Ben-David, Benjamin De Leon, John P. Sfakianos
Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive disease will be offered a radical treatment combined with systemic therapy, while in those with non-muscle-invasive disease, an attempt to resect the tumor endoscopically will usually be followed by different intravesical instillations
-
Liver Transplantation for Unresectable Colorectal Liver Metastasis: Perspective and Review of Current Literature Curr. Oncol. (IF 2.6) Pub Date : 2024-02-16 Todd J. Robinson, Kaelyn Cummins, Allan Tsung
The treatment of unresectable colorectal liver metastasis (CRLM) has previously been limited to palliative chemotherapy. Traditionally, the role of liver transplant has not been associated with sufficient survival to justify a patient undergoing a major operation with the associated requirement for postoperative immunosuppression. With improvements in chemotherapy options, a certain subset of patients
-
Learnings from Racialized Adolescents and Young Adults with Lived Experiences of Cancer: “It’s Okay to Critique the System That Claims to Save Us” Curr. Oncol. (IF 2.6) Pub Date : 2024-02-16 Tiffany T. Hill, Ian R. Cooper, Param K. Gill, Ada J. Okonkwo-Dappa, Cheryl H. Heykoop
Interest in AYA cancer care has increased globally over the recent past; however, most of this work disproportionately represents white, heterosexual, middle-income, educated, and able-bodied people. There is recognition in the literature that cancer care systems are not structured nor designed to adequately serve people of colour or other equity-denied groups, and the structural racism in the system
-
Effects of Group Exercise Intervention on Quality of Life and Physical Parameters in Patients with Childhood Cancer: A Systematic Review Curr. Oncol. (IF 2.6) Pub Date : 2024-02-15 Yurina Doi, Masato Ogawa, Kodai Ishihara, Junichiro Inoue, Kazuhiro P. Izawa
Background: Although the survival rates of childhood cancer are increasing, children diagnosed as having cancer experience psychological and physical problems and a declining quality of life (QOL). Methods: A systematic review of PubMed databases was conducted up to September 2023 to identify studies reporting the effects of group exercise intervention in children with cancer. The inclusion criteria
-
Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes Curr. Oncol. (IF 2.6) Pub Date : 2024-02-14 Andrew Baird, Abdullah Nasser, Peter Tanuseputro, Colleen Webber, Paul Wheatley-Price, Camille Munro
Malignant pleural mesothelioma is a rare, aggressive, and incurable cancer with a poor prognosis and high symptom burden. For these patients, little is known about the impact of palliative care consultation on outcomes such as mortality, hospital admissions, or emergency department visits. The aim of this study is to determine if referral to supportive and palliative care in patients with malignant
-
The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating it to Patients Curr. Oncol. (IF 2.6) Pub Date : 2024-02-13 Paolo Maione, Rosario Salvi, Cesare Gridelli
Patients with radically resected stage II and III NSCLC are exposed to a high risk of disease recurrence. Thus, adjuvant cisplatin-based chemotherapy is routinely offered to this patient population, although it results in an absolute increase in 5-year survival rate of only 4%. This modest improvement in survival rate makes it challenging to communicate to our patients about the decision to be treated
-
Insulin Resistance: The Increased Risk of Cancers Curr. Oncol. (IF 2.6) Pub Date : 2024-02-13 Leszek Szablewski
Insulin resistance, also known as impaired insulin sensitivity, is the result of a decreased reaction of insulin signaling to blood glucose levels. This state is observed when muscle cells, adipose tissue, and liver cells, improperly respond to a particular concentration of insulin. Insulin resistance and related increased plasma insulin levels (hyperinsulinemia) may cause metabolic impairments, which
-
Electromagnetic Transmitter-Based Prostate Gating for Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy: An Evaluation of Intrafraction Motion Curr. Oncol. (IF 2.6) Pub Date : 2024-02-09 Berardino De Bari, Geoffroy Guibert, Sabrine Slimani, Yanes Bashar, Terence Risse, Nicole Guisolan, Juliane Trouillot, Jonathan Abel, Patrick Weber
Background: Stereotactic Body Radiotherapy (SBRT) is as a standard treatment for prostate cancer (PCa). Tight margins and high dose gradients are needed, and the precise localization of the target is mandatory. Our retrospective study reports our experience regarding the evaluation of intrafraction prostate motion during LINAC-based SBRT evaluated with a novel electromagnetic (EM) tracking device.
-
Personalizing the Treatment of Women with Ductal Carcinoma In Situ (DCIS) Using the DCIS Score: A Qualitative Study on Score Use Curr. Oncol. (IF 2.6) Pub Date : 2024-02-10 Mary Ann O’Brien, Lawrence Paszat, Tutsirai Makuwaza, Cindy Fong, Eileen Rakovitch
Background: A twelve-gene molecular expression assay (DCIS score) may help guide radiation oncology treatment under specific circumstances. We undertook a study to examine radiation oncologist (RO), surgeon, and decision maker views on implementing the DCIS score in practice for women with low-risk DCIS. Methods: We conducted a qualitative study involving telephone interviews that were audio-recorded
-
Virtual Care for Patients with Advanced Well Differentiated Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Curr. Oncol. (IF 2.6) Pub Date : 2024-02-08 William J. Phillips, Michelle Pradier, Rachel Goodwin, Michael Vickers, Tim Asmis
Introduction: The COVID-19 pandemic resulted in an unprecedent shift towards virtual cancer care, including the care of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The aim of this study was to evaluate the use of virtual care for GEP-NETs during the COVID-19 pandemic at a high-volume academic cancer center. Methods: This retrospective, observational study performed at the Ottawa Hospital
-
Interventions to Mitigate Financial Toxicity in Adult Patients with Cancer in the United States: A Scoping Review Curr. Oncol. (IF 2.6) Pub Date : 2024-02-06 Seiichi Villalona, Brenda S. Castillo, Carlos Chavez Perez, Alana Ferreira, Isoris Nivar, Juan Cisneros, Carmen E. Guerra
Financial toxicity adversely affects quality of life and treatment outcomes for patients with cancer. This scoping review examined interventions aimed at mitigating financial toxicity in adult patients with cancer and their effectiveness. We utilized five bibliographical databases to identify studies that met our inclusion criteria. The review included studies conducted among adult patients with cancer
-
Quality of Life Following the Surgical Management of Gastric Cancer Using Patient-Reported Outcomes: A Systematic Review Curr. Oncol. (IF 2.6) Pub Date : 2024-02-04 Patrick Cullen Vallance, Lloyd Mack, Antoine Bouchard-Fortier, Evan Jost
Introduction: Surgical management of gastric adenocarcinoma can have a drastic impact on a patient’s quality of life (QoL). There is high variability among surgeons’ preferences for the type of resection and reconstructive method. Peri-operative and cancer-specific outcomes remain equivalent between the different approaches. Therefore, postoperative quality of life can be viewed as a deciding factor
-
Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques Curr. Oncol. (IF 2.6) Pub Date : 2024-02-05 Andreas F. Mavrogenis, Pavlos Altsitzioglou, Shinji Tsukamoto, Costantino Errani
Biopsy is a pivotal component in the diagnostic process of bone and soft tissue tumors. The objective is to obtain adequate tissue without compromising local tumor dissemination and the patient’s survival. This review explores contemporary principles and practices in musculoskeletal biopsies, emphasizing the critical role of diagnostic accuracy while also delving into the evolving landscape of liquid
-
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications Curr. Oncol. (IF 2.6) Pub Date : 2024-02-06 Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
The purpose of this study is to evaluate the treatment safety of thermal ablation compared to surgical treatment of T1a tumors (small renal masses) at a high-volume center. We conducted an observational single-center study based on data collected form the National Swedish Kidney Cancer Register (NSKCR) between 2015 and 2021. In total, 444 treatments of T1a tumors were included. Patients underwent surgery
-
Papillary Thyroid Microcarcinoma: Differences between Lesions in Incidental and Nonincidental Settings—Considerations on These Clinical Entities and Personal Experience Curr. Oncol. (IF 2.6) Pub Date : 2024-02-06 Giorgio Lucandri, Giulia Fiori, Francesco Falbo, Vito Pende, Massimo Farina, Paolo Mazzocchi, Assunta Santonati, Daniela Bosco, Antonio Spada, Emanuele Santoro
Papillary thyroid microcarcinoma (PTMC) represents 35–40% of all papillary cancers; it is defined as a nodule ≤ 10 mm at the time of histological diagnosis. The clinical significance of PTMC is still controversial, and it may be discovered in two settings: incidental PTMC (iPTMC), in which it is identified postoperatively upon histological examination of thyroid specimens following thyroid surgery
-
Expectations and Experiences of Participating in a Supervised and Home-Based Physical Exercise Intervention in Patients with Head and Neck Cancer during Chemoradiotherapy: A Qualitative Study Curr. Oncol. (IF 2.6) Pub Date : 2024-02-04 Annemieke Kok, Ellen Passchier, Anne M. May, Harriët Jager-Wittenaar, Cindy Veenhof, Remco de Bree, Martijn M. Stuiver, Caroline M. Speksnijder
(1) Background: Chemoradiotherapy (CRT) for head and neck cancer (HNC) is associated with severe toxicity resulting in fatigue and weight loss, including loss of skeletal muscle mass. Exercise interventions might positively affect physical fitness and quality of life. Sufficient adherence and compliance rates are necessary for optimal effects. This study aimed to gain insight into expectations and
-
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study Curr. Oncol. (IF 2.6) Pub Date : 2024-02-03 Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Kenichi Harada, Motonobu Nakamura, Naohiro Fujimoto
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. Hence, this study aimed to assess the oncological outcomes of patients with SUC treated with EV for metastatic disease. We retrospectively evaluated consecutive
-
Diagnostic Accuracy of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Muscle-Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis Curr. Oncol. (IF 2.6) Pub Date : 2024-02-01 Antonio Tufano, Davide Rosati, Martina Moriconi, Valerio Santarelli, Vittorio Canale, Stefano Salciccia, Alessandro Sciarra, Giorgio Franco, Vito Cantisani, Giovanni Battista Di Pierro
Background: Contrast-enhanced ultrasound (CEUS) is a diagnostic tool that is gaining popularity for its ability to improve overall diagnostic accuracy in bladder cancer (BC) staging. Our aim is to determine the cumulative diagnostic performance of CEUS in predicting preoperative muscle invasiveness using a comprehensive systematic review and pooled meta-analysis. Methods: A systematic review until
-
Geotemporal Fluorophore Biodistribution Mapping of Colorectal Cancer: Micro and Macroscopic Insights Curr. Oncol. (IF 2.6) Pub Date : 2024-02-02 Niall P. Hardy, Niall Mulligan, Jeffrey Dalli, Jonathan P. Epperlein, Peter M. Neary, William Robertson, Richard Liddy, Stephen D. Thorpe, John J. Aird, Ronan A. Cahill
Fluorescence-guided oncology promises to improve both the detection and treatment of malignancy. We sought to investigate the temporal distribution of indocyanine green (ICG), an exogenous fluorophore in human colorectal cancer. This analysis aims to enhance our understanding of ICG’s effectiveness in current tumour detection and inform potential future diagnostic and therapeutic enhancements. Methods:
-
Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma Curr. Oncol. (IF 2.6) Pub Date : 2024-02-01 Jane E. Rogers, Jaffer Ajani
Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor receptor-2 (HER-2) represented the single target in GACs for many years, seen in approximately 20% of patients with advanced GAC. Recent advances in
-
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma Curr. Oncol. (IF 2.6) Pub Date : 2024-02-01 Kamil J. Synoradzki, Natalia Paduszyńska, Malgorzata Solnik, Mario Damiano Toro, Krzysztof Bilmin, Elżbieta Bylina, Piotr Rutkowski, Yacoub A. Yousef, Claudio Bucolo, Sandrine Anne Zweifel, Michele Reibaldi, Michal Fiedorowicz, Anna M. Czarnecka
Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials
-
Disruptions in Cancer Care Due to the COVID-19 Pandemic and Fear of Cancer Recurrence in Women with Breast Cancer: A Mixed-Methods Study Curr. Oncol. (IF 2.6) Pub Date : 2024-02-01 Claudia Mc Brearty, Laurie Bisaillon, Michel Dorval, Hermann Nabi, Christine Desbiens, Julie Lemieux, Valérie Théberge, Amel Baghdadli, Sophie Lauzier, Josée Savard
Objective. This study investigated if fear of cancer recurrence (FCR) levels and the proportion of women having a clinical level of FCR differed by whether women had or had not experienced disruptions in their cancer tests and treatments due to the pandemic. Methods. We conducted a mixed-methods study between November 2020 and March 2021 among women diagnosed with breast cancer in the previous five
-
Acute Diabetes-Related Complications in Patients Receiving Chemoradiotherapy for Head and Neck Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-02-01 Rhiannon Mellor, Christian M. Girgis, Anthony Rodrigues, Charley Chen, Sonia Cuan, Parvind Gambhir, Lakmalie Perera, Michael Veness, Purnima Sundaresan, Bo Gao
Patients with cancer and diabetes face unique challenges. Limited data are available on diabetes management in patients undergoing concurrent chemoradiotherapy (CCRT), a curative intent anticancer therapy commonly associated with glucocorticoid administration, weight fluctuations and enteral feeds. This retrospective case–control study examined the real-world incidence of acute diabetes-related complications